TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed severe preeclampsia diagnosed prior to delivery~   Preeclampsia defined as: Blood pressure \> 140/90 AND proteinuria \> 300mg/24 hours OR 2+ on repeat dip stick~   Severe Preeclampsia defined as the presence of one or more of the following:~   i. systolic blood pressure ≥ 160mmHg or diastolic blood pressure ≥ 110 mmHg on 2 occasions at least 4 hours apart~   ii. new-onset cerebral or visual disturbance~   iii. severe persistent right upper quadrant pain or serum transaminase concentrations ≥ 2 times the upper limit of normal~   iv. thrombocytopenia (platelets \< 100 x 109/L)~   v. renal insufficiency (serum creatinine \> 97.2 umol/L)~   vi. pulmonary edema~2. A singleton gestation~3. Gestation between 24+0/7 to 40+6/7 weeks.Exclusion Criteria:~Exclusion Criteria:~1. Multiple pregnancy~2. Chronic hypertension or other condition requiring the use of BP-lowering medication~3. Cardiovascular disorders: Unstable angina pectoris, heart failure, life-threatening arrhythmia, atrial fibrillation, kidney failure~4. Known allergy or sensitivity to aspirin used in the study~5. Any medical comorbidity that is a contraindication to LD-ASA: Hemophilia or other bleeding disorder, history of GI bleeding, renal failure, severe liver disease, thrombocytopenia, gout, G6PD deficiency~6. Recent history of drug/alcohol abuse (\< 1 year prior to delivery), or receiving treatment for such~7. Nasal polyps~8. Hypercholesterolemia requiring pharmaceutical treatment~9. Raynaud's phenomenon~10. Collagen-vascular disease: lupus, scleroderma, rheumatoid arthritis~11. History of pre-existing diabetes~12. Ongoing use of any of the following medications: methotrexate, anti-coagulants, thrombolytics, oral hypoglycemics, uricsuric agents, valproic acid, glucocorticosteroids, digoxin

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PO LD-ASA (Type: EXPERIMENTAL): Study participants who are assigned to the oral aspirin arm of the study will receive 81mg oral aspirin. Over-encapsulated 81mg aspirin tablets will be used. Study participants in this arm will take 81mg aspirin daily for 6 months.
- PO Placebo (Type: PLACEBO_COMPARATOR): A standard placebo pill, the same size, shape and color of the oral aspirin will be used. The placebo pills will be over-encapsulated in the same manner as the aspirin tablets. The placebo will be administered to the participants randomized to placebo group in the same manner the oral aspirin would be administered - they will take the pill daily for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed squamous cell carcinoma of the head and neck~  * Stage IVA or IVB disease~    * Stage III disease allowed provided patient may benefit from organ preservation or patient refused surgery~* Measurable or evaluable disease~* ECOG performance status 0-2~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Creatinine ≤ 1.5 mg/dL OR glomerular filtration rate ≥ 60 mL/min~* Bilirubin normal~* Alkaline phosphatase (AP) and AST or ALT must be within the following ranges:~  * AP normal AND AST or ALT ≤ 5 times upper limit of normal (ULN)~ * AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN~ * AP ≤ 5 times ULN AND AST or ALT normal~Exclusion Criteria:~* Salivary gland, sinus, or nasopharyngeal primary disease~* Evidence of distant metastatic disease~* Pregnant or nursing~* Positive pregnancy test (Fertile patients must use effective contraception during study treatment and for 3 months after completion of study treatment)~* Other malignancy within the past 5 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other malignancy in which stage and nature of disease is such that it is unlikely to affect survival for the next 3 years~* Peripheral neuropathy ≥ grade 2~* Hearing loss ≥ grade 2~* Severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 and/or cisplatin or other platinum analogs~* Poor nutritional status, in the opinion of the investigator~* Active infection~* Active ischemic heart disease~* Myocardial infarction within the past 6 months~* Prior radiotherapy above the clavicles~* Prior chemotherapy~* Prior surgery to the primary tumor except biopsy~* Concurrent amifostine or other investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy + Low Dose Radiation (Type: EXPERIMENTAL): Patients receiving chemotherapy and Low Dose (60 Gy) Radiation per protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Type 2 Diabetes Mellitus~* Prescribed Saxagliptin by patient's attending physician~Exclusion Criteria:~* Known allergic or serious adverse reaction to Saxagliptin~* Pregnant or breastfeeding patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* HBeAg-positive serologically proven chronic hepatitis B with or without cirrhosis~* Elevated serum ALT \> ULN (upper limit of normal) but \</= 10 x ULN~* Patients with no contra-indications to Pegasys therapy as detailed in the label~* Written informed consent where local regulations allow or require it~Exclusion Criteria:~* Patients should not receive concomitant therapy with telbivudine~* Co-infection with hepatitis A, hepatitis B or HIV~* Pregnant or breastfeeding women~* Patients with depression/mental diseases~* Neutrophil at baseline \> 90.000/mm3~* Abnormal T4 or TSH

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed SCLC~* Extensive stage~* No prior chemotherapy~* WHO PS 0-3~* Adequate organ function (liver, kidney)~* Adequate hematology (bone marrow)~* Informed consent~Exclusion Criteria:~* PS 4~* Inadequate organ function~* Uncontrolled infection~* Concomitant major medical contraindications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Topotecan + cisplatin
- B (Type: ACTIVE_COMPARATOR): Etoposide + carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Accelerated Bilateral rTMS on Geriatric Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 60-85 years~* literate and received basic education for at least 2 years~* diagnosis of major depressive disorder, without psychotic features, according to DSM-5~* have a score of 20 or greater on the 17-item Hamilton Depression Rating Scale~* failed to achieve clinical response by at least 1 antidepressant trial of sufficient dosage for at least 4 weeks~* psychoactive agents were in stable doses before randomization~Exclusion Criteria:~* active suicide plans or attempts; or suicide attempts in the last 12 months~* diagnosis of schizophrenia or bipolar disorder according to DSM-5~* have DSM-5-confirmed substance use disorder (excluding tobacco) in the last 3 months~* have delirium, major neurocognitive disorder or MMSE \< 24~* current use of bupropion \>300 mg/day, tricyclic antidepressant, clozapine, chlorpromazine, foscarnet, ganciclovir, ritonavir, theophylline or anti-epileptic agents excluding benzodiazepines~* history of severe head trauma, epilepsy, multiple sclerosis, stroke, brain tumors, intracranial aneurysm, active intracranial infection, increased intracranial pressure, metallic implants in the brain, major brain surgery or major neurological diseases~* with a cardiac pacemaker or defibrillator~* received rTMS treatment before

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Group (Type: EXPERIMENTAL): The experimental group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by low-frequency (1Hz) inhibition at right DLPFC (120% motor threshold, 10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't active-R't active-1.5 hr-L't active-R't active), five days a week, and two weeks in total.
- Standard Treatment Group (Type: ACTIVE_COMPARATOR): The standard treatment group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by sham inhibition at right DLPFC (1Hz, 10 trains, 1200 pulses); after a 1.5-hour inter-session interval, a sham session would be administered at left and right DLPFC (L't active-R't sham-1.5 hr-L't sham-R't sham. The course would be applied five days a week, and two weeks in total.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age superior or equal 18 years~* primitive ovarian adenocarcinoma histologically confirmed~* or peritoneal or fallopian tube adenocarcinoma histologically confirmed~* Progression or relapse within 12 months after the end of first line of platin based chemotherapy~* association in first line with other anticancer agent is allowed (taxanes, anthracyclines, alkylants or gemcitabine) and with an anti-angiogenic (bevacizumab, sunitinib).~* intra-peritoneal chemotherapy in first line is possible~* No previous treatment with HER inhibitors (ex : gefitinib)~* HER status not necessary~* measurable lesions (RECIST criteria). and/or CA125 value higher than 2 fold the normal value or CA125 higher than 2 fold nadir value (if no normalized) proved by two samples distant of 1 month~* OMS inferior or equal 2.~* biological parameters as follow: creatininemia ≤ 150 µmol/L or clearance ≥ 50 mL/min,bilirubin ≤ 1,5 LNS,transaminases and or alcalin phosphatases ≤ 2 LNS without hepatic metastasis or ≤ 3 LNS if hepatic metastasis,neutrophils ≥ 1,5.109/L,plaquettes ≥ 100.109/L.~* normal FEV~* No previous treatment by chemotherapy, hormonotherapy, immunotherapy or radiotherapy within 4 weeks before inclusion~* No concomitant treatment forbidden with lapatinib.~* No previous treatment by Amiodarone in 6 months before inclusion~* signed informed consent~Exclusion Criteria:~* Previous treatment with :~  * intensive chemotherapy with autograft~ * two lignes of chemotherapy~ * previous total abdominal irradiation~ * previous chemotherapy with anti-HER treatment~* History of brain or meningitis metastasis uncontrolled.~* Malignancies except for adequately treated carcinoma in situ of the cervix and/or basal cell skin cancer.~* uncontrolled infectious pathology~* uncontrolled cardiovascular disease~* Patients with an active intestinal occlusion not permit oral treatment~* known hypersensibility to topotecan and its excipients~* Woman of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period~* Individual deprived of liberty

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed consent of an approved informed consent form~2. A. For the dose escalation phase: Patients with histological or cytological confirmed non-small cell lung cancer who are rated suitable for treatment with Erlotinib B. For MTD expansion phase: Patients diagnosed with non- small cell lung cancer rated suitable for treatment with Erlotinib and with measurable disease according to RECIST version 1.1~3. Performance status (ECOG) ≤ 2~4. Life expectancy at least 3 months~5. Age ≥ 18 years~6. Acceptable liver, kidney and bone marrow function, defined as:~   * Bilirubin ≤ 1.5 x upper limit of normal (ULN)~  * ASAT, ALAT and alkaline phosphatase ≤ 3 x ULN (if liver metastases is ≤ 5 x ULN allowed)~  * Serum creatinine ≤ 1.5 x upper limit of normal (ULN)~  * WBC\> 2.5 x 109 / l, neutrophils\> 1.0 x 109 / l, platelets\> 100 x 109 / l~  * Hemoglobin\> 9.0 g / dl or\> 5.6 mmol / l~7. Acceptable coagulation: PT and APTT within ≤ 1.5 x ULN or in the therapeutic range if given anticoagulant~8. A negative pregnancy test for women of childbearing age. In fertile men and women the use of effective contraception methods are required during the trial~9. Serum potassium within normal range~Exclusion Criteria:~1. Treatment with experimental drugs within the last 4 weeks~2. Former anti-cancer therapy within the last 3 weeks before the start of experimental treatment, including chemotherapy, radiotherapy, endocrine therapy or immunotherapy~3. Simultaneous presence of active infection or other concomitant present medical condition likely to affect the experimental procedures, including significant cardiovascular disease (New York Heart Association Class III or IV heart disease, myocardial infarction within the past 6 months, unstable angina, congestive heart failure requiring treatment, unstable arrhythmia or the need for antiarrhythmic drugs or signs of ischemia on ECG, marked baseline prolongation of QT / QTc interval, for example repeated demonstration of a QTc interval\> 500 msec; long QT syndrome; required the use of concurrent medication on dosage belinostat days, which may cause torsades de pointes (see Appendix 1).~4. Altered mental status that prevents understanding of the informed consent process and / or execution of the necessary experiments~5. Secondary malignancy present (previous malignancy accepted if cured by treatment for \> 3 years ago)~6. Intestinal obstruction or threatening bowel obstruction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belinostat, Erlotinib, NSCLC (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Enrollment 3-28 days after an acute myocardial infarction.~* Infarct related artery occlusion (TIMI 0 or 1).~* High risk: left ventricular ejection fraction (LVEF)\<50% or LVEF\>50% and proximal coronary occlusion.~* Preserved infarct zone viability (necrosis transmurality \<50% in at least 4 segments out of 17 according to AHA classification).~Exclusion Criteria:~* Unstable clinical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Optimal medical therapy (Type: ACTIVE_COMPARATOR): Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification
- PCI with optimal medical therapy (Type: EXPERIMENTAL): Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification plus percutaneous coronary intervention and coronary stenting

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Fasting in Refractory Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Experiencing at least 2 seizures per month~* .BMI of 25 or over~Exclusion Criteria:~* Current/previous eating disorder~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intermittent fasting (Type: EXPERIMENTAL): Patients consume their normal diet for 5 days in the week. On 2 days they only consume 500 Cals if female and 600 Cals if male.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Infant Nutrition and Risk of Celiac Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newborns and infants less than 6 months of age~* First-degree relatives of patients affected with biopsy-proven CD~* On exclusive milk diet (breast milk or formula)~Exclusion Criteria:~* Infants that have gluten introduced in their diet before 5-6 months of age~* Infants older than 6 months of age

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- 1 Gluten containing diet (Type: ACTIVE_COMPARATOR): Gluten added to diet at 6 months per American Academy of Pediatrics recommendations
- 2 Gluten free diet (Type: ACTIVE_COMPARATOR): Non gluten containing food starch added to diet from 6-12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 to 65 years, male or female~* In-patients suffering from schizophrenia according to DSM-IV diagnostic criteria with PANSS total score of greater than or equal to 60.~* Patients with PANSS-EC total score of greater than or equal to 14 and with at least one PANSS-EC symptom score greater than or equal to 4~Exclusion Criteria:~* Patients with history of seizure or with alcohol or substance abuse in the last 6 months~* Diabetes, Parkinson's disease or phaeochromocytoma~* Patients with hypertension and current use of antihypertensive agents~* Women who are pregnant, lactating or intend to become pregnant during the study period~* Poor response to two different antipsychotics in full dose and full course or use of clozapine previously~* Renal, hepatic, haematologic disease or other conditions may not suitable for the study based on investigator's evaluation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1. Zotepine (Type: EXPERIMENTAL): None
- 2. Risperidone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues